Equities analysts expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to post sales of $5.53 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Five Prime Therapeutics’ earnings, with the lowest sales estimate coming in at $2.00 million and the highest estimate coming in at $7.60 million. Five Prime Therapeutics reported sales of $7.58 million during the same quarter last year, which would suggest a negative year over year growth rate of 27%. The firm is scheduled to report its next earnings report on Wednesday, August 14th.
On average, analysts expect that Five Prime Therapeutics will report full year sales of $19.99 million for the current year, with estimates ranging from $5.30 million to $30.00 million. For the next year, analysts expect that the company will post sales of $60.28 million, with estimates ranging from $30.00 million to $139.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.05. The firm had revenue of $5.35 million for the quarter, compared to analyst estimates of $5.71 million. Five Prime Therapeutics had a negative return on equity of 54.87% and a negative net margin of 683.89%.
Several analysts have commented on FPRX shares. Guggenheim started coverage on Five Prime Therapeutics in a report on Friday, April 12th. They issued a “buy” rating and a $24.00 price objective on the stock. BidaskClub lowered Five Prime Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Cowen reissued a “buy” rating on shares of Five Prime Therapeutics in a report on Wednesday, February 27th. Zacks Investment Research lowered Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Finally, ValuEngine raised Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 20th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $19.88.
Several large investors have recently modified their holdings of the company. Quantamental Technologies LLC purchased a new position in Five Prime Therapeutics during the fourth quarter worth approximately $58,000. Federated Investors Inc. PA lifted its position in Five Prime Therapeutics by 2,119.8% during the first quarter. Federated Investors Inc. PA now owns 6,171 shares of the biotechnology company’s stock worth $82,000 after buying an additional 5,893 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in Five Prime Therapeutics by 1,929.9% during the first quarter. BNP Paribas Arbitrage SA now owns 7,328 shares of the biotechnology company’s stock worth $98,000 after buying an additional 6,967 shares in the last quarter. Jane Street Group LLC purchased a new position in Five Prime Therapeutics during the fourth quarter worth approximately $110,000. Finally, Metropolitan Life Insurance Co. NY lifted its position in Five Prime Therapeutics by 456.2% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 13,283 shares of the biotechnology company’s stock worth $124,000 after buying an additional 10,895 shares in the last quarter. 86.94% of the stock is currently owned by hedge funds and other institutional investors.
FPRX traded up $0.06 during trading on Friday, hitting $6.27. The company’s stock had a trading volume of 23,418 shares, compared to its average volume of 331,169. The company has a current ratio of 10.41, a quick ratio of 10.41 and a debt-to-equity ratio of 0.21. Five Prime Therapeutics has a twelve month low of $5.91 and a twelve month high of $17.88. The firm has a market cap of $227.20 million, a P/E ratio of -1.52 and a beta of 3.09.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
See Also: What is the Difference Between Common Shares and Convertible Shares?
Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.